| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2023 | 20.09% | Barclays | $118 → $110 | Maintains | Equal-Weight |
| 09/29/2023 | 31% | Oppenheimer | → $120 | Initiates Coverage On | → Outperform |
| 08/09/2023 | 27.73% | BMO Capital | $125 → $117 | Maintains | Market Perform |
| 08/09/2023 | 41.92% | Stephens & Co. | → $130 | Reiterates | Overweight → Overweight |
| 06/01/2023 | 28.82% | Barclays | $120 → $118 | Maintains | Equal-Weight |
| 05/04/2023 | 34.28% | BMO Capital | $115 → $123 | Maintains | Market Perform |
| 05/04/2023 | 41.92% | Stephens & Co. | $120 → $130 | Maintains | Overweight |
| 05/04/2023 | 31% | Barclays | $110 → $120 | Maintains | Equal-Weight |
| 04/14/2023 | 25.55% | BMO Capital | → $115 | Reinstates | → Market Perform |
| 04/13/2023 | 32.1% | UBS | $105 → $121 | Upgrades | Neutral → Buy |
| 03/17/2023 | 31% | Stephens & Co. | → $120 | Reiterates | → Overweight |
| 02/09/2023 | 20.09% | Credit Suisse | $100 → $110 | Maintains | Neutral |
| 01/23/2023 | 20.09% | Barclays | → $110 | Downgrades | Overweight → Equal-Weight |
| 01/17/2023 | 31% | Stephens & Co. | $100 → $120 | Upgrades | Equal-Weight → Overweight |
| 11/07/2022 | 9.17% | Credit Suisse | $94 → $100 | Maintains | Neutral |
| 09/30/2022 | -2.84% | UBS | → $89 | Initiates Coverage On | → Neutral |
| 04/12/2022 | 2.62% | Credit Suisse | $102 → $94 | Downgrades | Outperform → Neutral |
| 11/09/2021 | 25.55% | Barclays | → $115 | Initiates Coverage On | → Overweight |
| 11/03/2021 | 22.27% | BMO Capital | $92 → $112 | Upgrades | Market Perform → Outperform |
| 11/03/2021 | 20.09% | Credit Suisse | $93 → $110 | Upgrades | Neutral → Outperform |
| 05/05/2021 | 9.17% | Stephens & Co. | → $100 | Downgrades | Overweight → Equal-Weight |
| 02/04/2021 | -10.48% | Credit Suisse | $77 → $82 | Maintains | Neutral |
| 07/16/2020 | 14.63% | Berenberg | → $105 | Initiates Coverage On | → Buy |
| 05/06/2020 | 1.53% | BMO Capital | $104 → $93 | Maintains | Market Perform |
| 05/06/2020 | -1.75% | Credit Suisse | $94 → $90 | Maintains | Neutral |
| 03/26/2020 | -19.21% | Goldman Sachs | $79 → $74 | Upgrades | Sell → Neutral |
| 02/12/2020 | 13.54% | BMO Capital | $90 → $104 | Maintains | Market Perform |
| 02/12/2020 | 2.62% | Credit Suisse | $77 → $94 | Maintains | Neutral |
| 01/02/2020 | 25.55% | Stephens & Co. | $97 → $115 | Maintains | Overweight |
| 11/04/2019 | -15.94% | Credit Suisse | $80 → $77 | Maintains | Neutral |
| 10/08/2019 | 5.9% | Stephens & Co. | → $97 | Initiates Coverage On | → Overweight |
| 08/06/2019 | -7.21% | Citigroup | $95 → $85 | Maintains | Neutral |
| 07/23/2019 | -15.94% | Credit Suisse | $85 → $77 | Maintains | Neutral |
| 01/24/2019 | — | Vertical Research | Downgrades | Buy → Hold | |
| 11/02/2018 | — | Citigroup | Upgrades | Sell → Neutral |
What is the target price for Ingredion (INGR)?
The latest price target for Ingredion (NYSE: INGR) was reported by Barclays on November 1, 2023. The analyst firm set a price target for $110.00 expecting INGR to rise to within 12 months (a possible 20.09% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ingredion (INGR)?
The latest analyst rating for Ingredion (NYSE: INGR) was provided by Barclays, and Ingredion maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Ingredion (INGR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ingredion, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ingredion was filed on November 1, 2023 so you should expect the next rating to be made available sometime around November 1, 2024.
Is the Analyst Rating Ingredion (INGR) correct?
While ratings are subjective and will change, the latest Ingredion (INGR) rating was a maintained with a price target of $118.00 to $110.00. The current price Ingredion (INGR) is trading at is $91.60, which is out of the analyst's predicted range.